CA3254948A1 - Polytherapy for the treatment of cancer - Google Patents
Polytherapy for the treatment of cancerInfo
- Publication number
- CA3254948A1 CA3254948A1 CA3254948A CA3254948A CA3254948A1 CA 3254948 A1 CA3254948 A1 CA 3254948A1 CA 3254948 A CA3254948 A CA 3254948A CA 3254948 A CA3254948 A CA 3254948A CA 3254948 A1 CA3254948 A1 CA 3254948A1
- Authority
- CA
- Canada
- Prior art keywords
- azd5305
- pharmaceutically acceptable
- acceptable salt
- darolutamide
- prostate cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362612P | 2022-04-07 | 2022-04-07 | |
| US63/362,612 | 2022-04-07 | ||
| PCT/EP2023/059126 WO2023194528A1 (en) | 2022-04-07 | 2023-04-06 | Combination therapy for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3254948A1 true CA3254948A1 (en) | 2023-10-12 |
Family
ID=86185292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3254948A Pending CA3254948A1 (en) | 2022-04-07 | 2023-04-06 | Polytherapy for the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250235448A1 (https=) |
| EP (1) | EP4504180A1 (https=) |
| JP (1) | JP2025511401A (https=) |
| KR (1) | KR20240170956A (https=) |
| CN (1) | CN118973572A (https=) |
| AU (1) | AU2023248685A1 (https=) |
| CA (1) | CA3254948A1 (https=) |
| IL (1) | IL316016A (https=) |
| MX (1) | MX2024012368A (https=) |
| TW (1) | TW202404593A (https=) |
| WO (1) | WO2023194528A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026021478A1 (zh) * | 2024-07-23 | 2026-01-29 | 江苏恒瑞医药股份有限公司 | Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
-
2023
- 2023-04-06 WO PCT/EP2023/059126 patent/WO2023194528A1/en not_active Ceased
- 2023-04-06 US US18/853,491 patent/US20250235448A1/en active Pending
- 2023-04-06 AU AU2023248685A patent/AU2023248685A1/en active Pending
- 2023-04-06 KR KR1020247036943A patent/KR20240170956A/ko active Pending
- 2023-04-06 CN CN202380032429.6A patent/CN118973572A/zh active Pending
- 2023-04-06 CA CA3254948A patent/CA3254948A1/en active Pending
- 2023-04-06 JP JP2024559034A patent/JP2025511401A/ja active Pending
- 2023-04-06 EP EP23719307.3A patent/EP4504180A1/en active Pending
- 2023-04-06 IL IL316016A patent/IL316016A/en unknown
- 2023-04-07 TW TW112112999A patent/TW202404593A/zh unknown
-
2024
- 2024-10-04 MX MX2024012368A patent/MX2024012368A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012368A (es) | 2024-11-08 |
| AU2023248685A1 (en) | 2024-11-14 |
| CN118973572A (zh) | 2024-11-15 |
| IL316016A (en) | 2024-11-01 |
| TW202404593A (zh) | 2024-02-01 |
| US20250235448A1 (en) | 2025-07-24 |
| EP4504180A1 (en) | 2025-02-12 |
| JP2025511401A (ja) | 2025-04-15 |
| KR20240170956A (ko) | 2024-12-05 |
| WO2023194528A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202425976A (zh) | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 | |
| US20250213556A1 (en) | Combination therapy for treating cancer | |
| CA3254948A1 (en) | Polytherapy for the treatment of cancer | |
| AU2021206140A1 (en) | Combination therapy for treating cancer | |
| US20250228847A1 (en) | Combination therapy for treating cancer | |
| KR20260010420A (ko) | 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용 | |
| EP4364742A1 (en) | Pharmaceutical composition for treating solid tumors | |
| KR20240148328A (ko) | 전이성 거세 저항성 전립선암 및 hrr 변형을 갖는 환자에서 임상 결과를 개선하기 위한 니라파립 및 아비라테론 아세테이트와 프레드니손 | |
| TW202600137A (zh) | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 | |
| KR20250023494A (ko) | 암 치료를 위한 병용 요법 | |
| CN116600804A (zh) | 用于治疗雄激素受体突变的前列腺癌的ezh2抑制疗法 | |
| WO2022191870A1 (en) | Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene | |
| JP2022547311A (ja) | 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240923 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250213 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260319 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260319 |